Why the study?
Does adjuvant chemotherapy with vincristine, actinomycin D, and cyclophosphamide improve disease-free survival in patients with non-metastatic osteosarcoma following surgical amputation?
Population
12 patients with osteosarcoma without metastases, following surgical amputation for the primary lesion
Design
Case_series
Follow-up
54 months or longer
Authors
Loading...
Hypothesis-generating for adjuvant chemotherapy in osteosarcoma; does not support practice change without randomized data.
Does adjuvant chemotherapy with vincristine, actinomycin D, and cyclophosphamide improve disease-free survival in patients with non-metastatic osteosarcoma following surgical amputation?
A 3-drug adjuvant chemotherapy regimen (vincristine, actinomycin D, cyclophosphamide) resulted in a 33% disease-free survival rate at 54+ months in patients with non-metastatic osteosarcoma post-amputation.
Sutow et al. (1975) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: